

BME - GROWTH
Palacio de la Bolsa
Plaza de la Lealtad, 1
28014 Madrid

Alicante, 7th January 2022

COMUNICACION- OTHER RELEVANT INFORMATION- FACEPHI BIOMETRIA, S.A.

Dear Sirs,

Under the provisions of article 17 of the Regulation (EU) No. 596/2014 on market abuse, and article 228 of the consolidated text of the Spanish Securities Market Law, approved by the Royal Legislative Decree 4/2015, of 23rd October, and related provisions, as well as in the Circular 3/2020 of BME Growth, we inform you about the following information related to the company FACEPHI BIOMETRIA, S.A. (hereinafter "FacePhi" or "the Company", interchangeably).

OTHER RELEVANT INFORMATION

The Company has planned the following publication of results for the next dates:

Monday, February 7, before the stock market opening:

- Preview of financial results for 2021.

Friday, April 29, before the stock market opening:

- Independent audit report corresponding to the individual annual accounts of the Company for the year 2021.
- Annual accounts of the Company for the year 2021 prepared together with the management report.
- Independent audit report corresponding to the consolidated annual accounts of the Group for financial year 2021.
- Consolidated annual accounts of the Group corresponding to financial year 2021 prepared together with the management report.
- Report on the organizational structure and internal control system of the Group for compliance with the information obligations established by the Market.

In compliance with Circular 3/2020 of the segment BME Growth of BME MTF Equity, it is expressly stated that the information hereby communicated has been produced under the sole responsibility of the company and its administrators.

We remain at your disposal for any clarification you might deem necessary.



Sincerely,

Javier Mira Miró

Chairman of the Board of Directors